[Long-term follow-up of reconstruction of the pulmonary artery using homograft].

Y. Naito,Y. Kawashima,T. Fujita,T. Miyamoto,T. Mori

1972-05-01

Abstract:

What problem does this paper attempt to address?

Epidemiology of cardiogenic shock using the Shock Academic Research Consortium (SHARC) consensus definitions

David D Berg,Erin A Bohula,Siddharth M Patel,Carlos E Alfonso,Carlos L Alviar,Vivian M Baird-Zars,Christopher F Barnett,Gregory W Barsness,Courtney E Bennett,Sunit-Preet Chaudhry,Christopher B Fordyce,Shahab Ghafghazi,Umesh K Gidwani,Michael J Goldfarb,Jason N Katz,Venu Menon,P Elliott Miller,L Kristin Newby,Alexander I Papolos,Jeong-Gun Park,Matthew J Pierce,Alastair G Proudfoot,Shashank S Sinha,Lakshmi Sridharan,Andrea D Thompson,Sean van Diepen,David A Morrow

DOI: https://doi.org/10.1093/ehjacc/zuae098

2024-08-29

Abstract:Abstract Aims The Shock Academic Research Consortium (SHARC) recently proposed pragmatic consensus definitions to standardize classification of cardiogenic shock (CS) in registries and clinical trials. We aimed to describe contemporary CS epidemiology using the SHARC definitions in a cardiac intensive care unit (CICU) population. Methods and results The Critical Care Cardiology Trials Network (CCCTN) is a multinational research network of advanced CICUs coordinated by the TIMI Study Group (Boston, MA). Cardiogenic shock was defined as a cardiac disorder resulting in SBP < 90 mmHg for ≥30 min [or the need for vasopressors, inotropes, or mechanical circulatory support (MCS) to maintain SBP ≥ 90 mmHg] with evidence of hypoperfusion. Primary aetiologic categories included acute myocardial infarction-related CS (AMI-CS), heart failure-related CS (HF-CS), and non-myocardial (secondary) CS. Post-cardiotomy CS was not included. Heart failure-related CS was further subcategorized as de novo vs. acute-on-chronic HF-CS. Patients with both cardiogenic and non-cardiogenic components of shock were classified separately as mixed CS. Of 8974 patients meeting shock criteria (2017–23), 65% had isolated CS and 17% had mixed shock. Among patients with CS (n = 5869), 27% had AMI-CS (65% STEMI), 59% HF-CS (72% acute-on-chronic, 28% de novo), and 14% secondary CS. Patients with AMI-CS and de novo HF-CS were most likely to have had concomitant cardiac arrest (P < 0.001). Patients with AMI-CS and mixed CS were most likely to present in more severe shock stages (SCAI D or E; P < 0.001). Temporary MCS use was highest in AMI-CS (59%). In-hospital mortality was highest in mixed CS (48%), followed by AMI-CS (41%), similar in de novo HF-CS (31%) and secondary CS (31%), and lowest in acute-on-chronic HF-CS (25%; P < 0.001). Conclusion SHARC consensus definitions for CS classification can be pragmatically applied in contemporary registries and reveal discrete subpopulations of CS with distinct phenotypes and outcomes that may be relevant to clinical practice and future research.

cardiac & cardiovascular systems
Phenotyping Cardiogenic Shock

Elric Zweck,Katherine L Thayer,Ole K L Helgestad,Manreet Kanwar,Mohyee Ayouty,A Reshad Garan,Jaime Hernandez-Montfort,Claudius Mahr,Detlef Wencker,Shashank S Sinha,Esther Vorovich,Jacob Abraham,William O'Neill,Song Li,Gavin W Hickey,Jakob Josiassen,Christian Hassager,Lisette O Jensen,Lene Holmvang,Henrik Schmidt,Hanne B Ravn,Jacob E Møller,Daniel Burkhoff,Navin K Kapur

DOI: https://doi.org/10.1161/JAHA.120.020085

2021-07-20

Abstract:Background Cardiogenic shock (CS) is a heterogeneous syndrome with varied presentations and outcomes. We used a machine learning approach to test the hypothesis that patients with CS have distinct phenotypes at presentation, which are associated with unique clinical profiles and in-hospital mortality. Methods and Results We analyzed data from 1959 patients with CS from 2 international cohorts: CSWG (Cardiogenic Shock Working Group Registry) (myocardial infarction [CSWG-MI; n=410] and acute-on-chronic heart failure [CSWG-HF; n=480]) and the DRR (Danish Retroshock MI Registry) (n=1069). Clusters of patients with CS were identified in CSWG-MI using the consensus k means algorithm and subsequently validated in CSWG-HF and DRR. Patients in each phenotype were further categorized by their Society of Cardiovascular Angiography and Interventions staging. The machine learning algorithms revealed 3 distinct clusters in CS: "non-congested (I)", "cardiorenal (II)," and "cardiometabolic (III)" shock. Among the 3 cohorts (CSWG-MI versus DDR versus CSWG-HF), in-hospital mortality was 21% versus 28% versus 10%, 45% versus 40% versus 32%, and 55% versus 56% versus 52% for clusters I, II, and III, respectively. The "cardiometabolic shock" cluster had the highest risk of developing stage D or E shock as well as in-hospital mortality among the phenotypes, regardless of cause. Despite baseline differences, each cluster showed reproducible demographic, metabolic, and hemodynamic profiles across the 3 cohorts. Conclusions Using machine learning, we identified and validated 3 distinct CS phenotypes, with specific and reproducible associations with mortality. These phenotypes may allow for targeted patient enrollment in clinical trials and foster development of tailored treatment strategies in subsets of patients with CS.
Association of Hemometabolic Trajectory and Mortality: Insights From the Cardiogenic Shock Working Group Registry

Wissam Khalife,Manreet K Kanwar,Jacob Abraham,Song Li,Kevin John,Shashank S Sinha,Elric Zweck,Borui Li,Arthur R Garan,Jaime Hernandez-Montfort,Yijing Zhang,VAN-Khue Ton,Maya Guglin,Rachna Kataria,Gavin W Hickey,Saraschandra Vallabhajosyula,Chloe Kong,Maryjane Farr,Justin Fried,Shelley Hall,Neil M Harwani,Claudius Mahr,Sandeep Nathan,Paavni Sangal,Andrew Schwartzman,Arvind Bhimaraj,J U Kim,Alec A Vishnevsky,Esther Vorovich,Karol D Walec,Peter Zazzali,Aiham Albaeni,Daniel Burkhoff,Navin K Kapur

DOI: https://doi.org/10.1016/j.cardfail.2024.06.019

Abstract:Cardiogenic shock (CS) is a hemodynamic syndrome that can progress to systemic metabolic derangements and end-organ dysfunction. Prior studies have reported hemodynamic parameters at the time of admission to be associated with mortality but hemodynamic trajectories in CS have not been well described. We studied the association between hemodynamic profiles and their trajectories and in-hospital mortality in patients with CS due to heart failure (HF-CS) and acute myocardial infarction (MI-CS). Using data from the large multicenter Cardiogenic Shock Working Group (CSWG) registry, we analyzed hemodynamic data obtained at the time of pulmonary artery catheter (PAC) insertion (dataset at baseline) and at PAC removal or death (dataset at final time point). Univariable regression analyses for prediction of in-hospital mortality were conducted for baseline and final hemodynamic values, as well as the interval change (delta-P). Data was further analyzed based on CS etiology and survival status. A total of 2260 patients with PAC data were included (70% male, age 61 ± 14 years, 61% HF-CS, 27% MI-CS). In-hospital mortality was higher in the MI-CS group (40.1%) compared with HF-CS (22.4%, P < .01). In the HF-CS cohort, survivors exhibited lower right atrial pressure (RAP), pulmonary artery pressure (PAP), cardiac output/index (CO/CI), lactate, and higher blood pressure (BP) than nonsurvivors at baseline. In this cohort, during hospitalization, improvement in metabolic (aspartate transaminase, lactate), BP, hemodynamic (RAP, pulmonary artery pulsatility index [PAPi], pulmonary artery compliance for right-sided profile and CO/CI for left-sided profile), had association with survival. In the MI-CS cohort, a lower systolic BP and higher PAP at baseline were associated with odds of death. Improvement in metabolic (lactate), BP, hemodynamic (RAP, PAPi for right-sided profile and CO/CI for left-sided profile) were associated with survival. In a large contemporary CS registry, hemodynamic trajectories had a strong association with short-term outcomes in both cohorts. These findings suggest the clinical importance of timing and monitoring hemodynamic trajectories to tailor management in patients with CS.
Evaluation of repeated machine learning-based phenotyping in patients with cardiogenic shock

E Zweck,M Kanwar,S Li,S S Sinha,A R Garan,J Hernandez-Montfort,J Abraham,A Polzin,M Kelm,D Burkhoff,N K Kapur

DOI: https://doi.org/10.1093/eurheartj/ehae666.1697

IF: 39.3

2024-10-30

European Heart Journal

Abstract:Background Cardiogenic shock (CS) is a highly mortal disease with variable clinical manifestations, severity, and in-hospital trajectories. Multiple clinical trials have failed to show an impact of therapies on outcomes, partly because they focus on etiology as a classifier, failing to capture the clinical heterogeneity. A phenotype-based approach to CS allows for a dynamic risk stratification based on disease severity. We have previously presented three CS phenotypes at baseline using machine learning-based algorithms: phenotype I (non-congested), II (cardiorenal), and III (cardiometabolic). However, little is known about the clinical course of these CS phenotypes during hospitalization and whether repeated phenotyping may provide additional insights. Purpose To assess relevance and prognostic impact of repetitive reassessment of CS phenotypes and their trajectories during the first 72h after CS diagnosis. Methods We included all-cause CS patients from the multi-center, multinational Cardiogenic Shock Working Group (CSWG) V3 and V4 registries (Yr. 2022-2023). Phenotypes were assigned by nearest centroid classification based on the centroids from the initial CSWG V1 (Yr. 2019) registry derivation cohort. Missing values required for phenotype assignment were imputed for all patients, but imputed values were only used for phenotype assignment and not reported as outcomes. Results A total of 4308 patients were included, of which 928 had CS due to myocardial infarction (MI-CS) and 2164 had CS due to heart failure (HF-CS). At time of diagnosis/ baseline, 1627 (37.8%), 1832 (42.5%), and 849 (19.7%) of patients were in phenotype I (non-congested), II (cardiorenal) and III (cardiometabolic), respectively. In MI-CS, patients were evenly distributed between the three phenotypes (35.5%, 34.4%, and 30.2%, respectively), whereas in HF-CS, non-congested and cardiorenal CS were more common than cardiometabolic shock (38.8%, 48.9%, and 12.3%, respectively). Within the first 12 hours, most patients in cardiorenal and cardiometabolic CS shifted to non-congested CS (Figure 1). In-hospital mortality in admission phenotype I, II, and III was 21.7%, 32.1%, and 50.1% (p<0.0001 for difference), respectively, in concordance with previous reports. When assessed at different time points, phenotypes II and III were associated with higher odds of mortality than phenotype I at 24h, 48h, and 72h after initial shock diagnosis (p≤0.03 for all, Figure 2). Conclusion Beyond baseline, re-assessment of machine learning-based CS phenotypes within the first 72h after CS diagnosis may provide additional prognostic insights. These data may inform future clinical trial design to tailor interventions to specific CS phenotypes.Figure 1Figure 2

cardiac & cardiovascular systems
Contemporary approach to cardiogenic shock care: a state-of-the-art review

Aditya Mehta,Ilan Vavilin,Andrew H. Nguyen,Wayne B. Batchelor,Vanessa Blumer,Lindsey Cilia,Aditya Dewanjee,Mehul Desai,Shashank S. Desai,Michael C. Flanagan,Iyad N. Isseh,Jamie L. W. Kennedy,Katherine M. Klein,Hala Moukhachen,Mitchell A. Psotka,Anika Raja,Carolyn M. Rosner,Palak Shah,Daniel G. Tang,Alexander G. Truesdell,Behnam N. Tehrani,Shashank S. Sinha

DOI: https://doi.org/10.3389/fcvm.2024.1354158

IF: 3.6

2024-03-13

Frontiers in Cardiovascular Medicine

Abstract:Cardiogenic shock (CS) is a time-sensitive and hemodynamically complex syndrome with a broad spectrum of etiologies and clinical presentations. Despite contemporary therapies, CS continues to maintain high morbidity and mortality ranging from 35 to 50%. More recently, burgeoning observational research in this field aimed at enhancing the early recognition and characterization of the shock state through standardized team-based protocols, comprehensive hemodynamic profiling, and tailored and selective utilization of temporary mechanical circulatory support devices has been associated with improved outcomes. In this narrative review, we discuss the pathophysiology of CS, novel phenotypes, evolving definitions and staging systems, currently available pharmacologic and device-based therapies, standardized, team-based management protocols, and regionalized systems-of-care aimed at improving shock outcomes. We also explore opportunities for fertile investigation through randomized and non-randomized studies to address the prevailing knowledge gaps that will be critical to improving long-term outcomes.

cardiac & cardiovascular systems
Prognostic Performance of the IABP-SHOCK II Risk Score Among Cardiogenic Shock Subtypes in the Critical Care Cardiology Trials Network Registry

Carlos L. Alviar,Boyangzi K. Li,Norma M. Keller,Erin Bohula-May,Christopher Barnett,David D. Berg,James A. Burke,Sunit-Preet Chaudhry,Lori B. Daniels,Andrew P DeFilippis,Daniel Gerber,James Horowitz,Jacob C. Jentzer,Praneeth Katrapati,Ellen Keeley,Patrick R. Lawler,Jeong-Gun Park,Shashank S. Sinha,Jeffrey Snell,Michael A. Solomon,Jeffrey Teuteberg,Jason N. Katz,Sean van Diepen,David A. Morrow

DOI: https://doi.org/10.1016/j.ahj.2023.12.018

IF: 5.099

2024-01-08

American Heart Journal

Abstract:Background Risk stratification has potential to guide triage and decision-making in cardiogenic shock (CS). We assessed the prognostic performance of the IABP-SHOCK II score, derived in Europe for acute myocardial infarct-related CS (AMI-CS), in a contemporary North American cohort, including different CS phenotypes. Methods The Critical Care Cardiology Trials Network (CCCTN) coordinated by the TIMI Study Group is a multicenter network of cardiac intensive care units (CICU). Participating centers annually contribute ≥2 months of consecutive medical CICU admissions. The IABP-SHOCK II risk score includes age >73 years, prior stroke, admission glucose >191 mg/dl, creatinine >1.5 mg/dl, lactate >5 mmol/l, and post-PCI TIMI flow grade <3. We assessed the risk score across various CS etiologies. Results Of 17,852 medical CICU admissions 5,340 patients across 35 sites were admitted with CS. In patients with AMI-CS (n=912), the IABP-SHOCK II score predicted a >3-fold gradient in in-hospital mortality (low risk = 26.5%, intermediate risk =52.2%, high risk = 77.5%, p<0.0001; c-statistic=0.67; Hosmer-Lemeshow p=0.79). The score showed a similar gradient of in-hospital mortality in patients with non-AMI-related CS (n=2,517, p<0.0001) and mixed shock (n=923, p<0.001), as well as in left ventricular (<0.0001), right ventricular (p = 0.0163) or biventricular (<0.0001) CS. The correlation between the IABP-SHOCK II score and SOFA was moderate (r 2 =0.17) and the IABP-SHOCK II score revealed a significant risk gradient within each SCAI Stage. Conclusions In an unselected international multicenter registry of patients admitted with CS, the IABP- SHOCK II score only moderately predicted in-hospital mortality in a broad population of CS regardless of etiology or irrespective of right, left, or bi-ventricular involvement.

cardiac & cardiovascular systems
Sex Differences in Characteristics, Resource Utilization, and Outcomes of Cardiogenic Shock: Data From the Critical Care Cardiology Trials Network (CCCTN) Registry

Lori B. Daniels,Nicholas Phreaner,David D. Berg,Erin A. Bohula,Sunit-Preet Chaudhry,Christopher B. Fordyce,Michael J. Goldfarb,Jason N. Katz,Benjamin B. Kenigsberg,Patrick R. Lawler,Miguel A. Martillo Correa,Alexander I. Papolos,Robert O. Roswell,Shashank S. Sinha,Sean van Diepen,Jeong-Gun Park,David A. Morrow,on behalf of the Critical Care Cardiology Trials Network Investigators

DOI: https://doi.org/10.1161/circoutcomes.123.010614

2024-06-22

Circulation Cardiovascular Quality and Outcomes

Abstract:Circulation: Cardiovascular Quality and Outcomes, Ahead of Print. BACKGROUND:Sex disparities exist in the management and outcomes of various cardiovascular diseases. However, little is known about sex differences in cardiogenic shock (CS). We sought to assess sex-related differences in the characteristics, resource utilization, and outcomes of patients with CS.METHODS:The Critical Care Cardiology Trials Network is a multicenter registry of advanced cardiac intensive care units (CICUs) in North America. Between 2018 and 2022, each center (N=35) contributed annual 2-month snapshots of consecutive CICU admissions. Patients with CS were stratified as either CS after acute myocardial infarction or heart failure–related CS (HF-CS). Multivariable logistic regression was used for analyses.RESULTS:Of the 22 869 admissions in the overall population, 4505 (20%) had CS. Among 3923 patients with CS due to ventricular failure (32% female), 1235 (31%) had CS after acute myocardial infarction and 2688 (69%) had HF-CS. Median sequential organ failure assessment scores did not differ by sex. Women with HF-CS had shorter CICU lengths of stay (4.5 versus 5.4 days;P<0.0001) and shorter overall lengths of hospital stay (10.9 versus 12.8 days;P<0.0001) than men. Women with HF-CS were less likely to receive pulmonary artery catheters (50% versus 55%;P<0.01) and mechanical circulatory support (26% versus 34%;P<0.0001) compared with men. Women with HF-CS had higher in-hospital mortality than men, even after adjusting for age, illness severity, and comorbidities (34% versus 23%; odds ratio, 1.76 [95% CI, 1.42–2.17]). In contrast, there were no significant sex differences in utilization of advanced CICU monitoring and interventions, or mortality, among patients with CS after acute myocardial infarction.CONCLUSIONS:Women with HF-CS had lower use of pulmonary artery catheters and mechanical circulatory support, shorter CICU lengths of stay, and higher in-hospital mortality than men, even after accounting for age, illness severity, and comorbidities. These data highlight the need to identify underlying reasons driving the differences in treatment decisions, so outcomes gaps in HF-CS can be understood and eliminated.

cardiac & cardiovascular systems
Mixed Cardiogenic Shock: A Proposal for Standardized Classification, a Hemodynamic Definition, and Framework for Management

Sean van Diepen,Janine Pöss,Janek M Senaratne,Ann Gage,David A Morrow

DOI: https://doi.org/10.1161/CIRCULATIONAHA.124.069508

IF: 37.8

2024-10-29

Circulation

Abstract:The classification of cardiogenic shock (CS) has evolved from a singular cold-and wet-hemodynamic profile. Data from registries and clinical trials have contributed to a broader recognition that although all patients with CS have insufficient cardiac output leading to end organ hypoperfusion, there is considerable variability in CS acuity, underlying etiologies, volume status, and systemic vascular resistance. Mixed CS can be broadly categorized as CS with at least 1 additional shock state. Mixed CS states are now the second leading cause of shock in contemporary coronary intensive care units, but there is little high-quality evidence to guide routine care, and there are no standardized classification frameworks or well-established hemodynamic definitions. This primer summarizes the current epidemiology and proposes a classification framework and invasive hemodynamic parameters to guide categorization that could be applied to help better phenotype patients captured in registries and trials, as well as guide management of mixed CS states.
American Heart Association Cardiogenic Shock Registry: Design and Implementation

David A. Morrow,Mariell Jessup,William T. Abraham,Michael Acker,Angeline Aringo,Wayne Batchelor,Joanna Chikwe,Shaina Costello,Stavros G. Drakos,Steven Farmer,Annetine Gelijns,Nicole Gillette,Judith S. Hochman,Maria Isler,Navin K. Kapur,Arman Kilic,Robert Kormos,Eldrin F. Lewis,JoAnn Lindenfeld,Pierluca Lombardi,Donna Mancini,Sunil V. Rao,Christine Rutan,Marc Samsky,Mitchell W. Krucoff

DOI: https://doi.org/10.1161/circoutcomes.123.010637

2024-06-20

Circulation Cardiovascular Quality and Outcomes

Abstract:Circulation: Cardiovascular Quality and Outcomes, Ahead of Print. BACKGROUND:Cardiogenic shock is a morbid complication of heart disease that claims the lives of more than 1 in 3 patients presenting with this syndrome. Supporting a unique collaboration across clinical specialties, federal regulators, payors, and industry, the American Heart Association volunteers and staff have launched a quality improvement registry to better understand the clinical manifestations of shock phenotypes, and to benchmark the management patterns, and outcomes of patients presenting with cardiogenic shock to hospitals across the United States.METHODS:Participating hospitals will enroll consecutive hospitalized patients with cardiogenic shock, regardless of etiology or severity. Data are collected through individual reviews of medical records of sequential adult patients with cardiogenic shock. The electronic case record form was collaboratively designed with a core minimum data structure and aligned with Shock Academic Research Consortium definitions. This registry will allow participating health systems to evaluate patient-level data including diagnostic approaches, therapeutics, use of advanced monitoring and circulatory support, processes of care, complications, and in-hospital survival. Participating sites can leverage these data for onsite monitoring of outcomes and benchmarking versus other institutions. The registry was concomitantly designed to provide a high-quality longitudinal research infrastructure for pragmatic randomized trials as well as translational, clinical, and implementation research. An aggregate deidentified data set will be made available to the research community on the American Heart Association's Precision Medicine Platform. On March 31, 2022, the American Heart Association Cardiogenic Shock Registry received its first clinical records. At the time of this submission, 100 centers are participating.CONCLUSIONS:The American Heart Association Cardiogenic Shock Registry will serve as a resource using consistent data structure and definitions for the medical and research community to accelerate scientific advancement through shared learning and research resulting in improved quality of care and outcomes of shock patients.

cardiac & cardiovascular systems
A Standardized and Comprehensive Approach to the Management of Cardiogenic Shock

Behnam N Tehrani,Alexander G Truesdell,Mitchell A Psotka,Carolyn Rosner,Ramesh Singh,Shashank S Sinha,Abdulla A Damluji,Wayne B Batchelor

DOI: https://doi.org/10.1016/j.jchf.2020.09.005

Abstract:Cardiogenic shock is a hemodynamically complex syndrome characterized by a low cardiac output that often culminates in multiorgan system failure and death. Despite recent advances, clinical outcomes remain poor, with mortality rates exceeding 40%. In the absence of adequately powered randomized controlled trials to guide therapy, best practices for shock management remain nonuniform. Emerging data from North American registries, however, support the use of standardized protocols focused on rapid diagnosis, early intervention, ongoing hemodynamic assessment, and multidisciplinary longitudinal care. In this review, the authors examine the pathophysiology and phenotypes of cardiogenic shock, benefits and limitations of current therapies, and they propose a standardized and team-based treatment algorithm. Lastly, they discuss future research opportunities to address current gaps in clinical knowledge.
Clinical Characteristics and Outcomes of Patients Suffering Acute Decompensated Heart Failure Complicated by Cardiogenic Shock

Christos P. Kyriakopoulos,Konstantinos Sideris,Iosif Taleb,Eleni Maneta,Rana Hamouche,Eleni Tseliou,Chong Zhang,Angela P. Presson,Elizabeth Dranow,Kevin S. Shah,Tara L. Jones,James C. Fang,Josef Stehlik,Craig H. Selzman,Matthew L. Goodwin,Joseph E. Tonna,Thomas C. Hanff,Stavros G. Drakos

DOI: https://doi.org/10.1161/circheartfailure.123.011358

2024-09-02

Circulation Heart Failure

Abstract:Circulation: Heart Failure, Ahead of Print. BACKGROUND:Cardiogenic shock (CS) can stem from multiple causes and portends poor prognosis. Prior studies have focused on acute myocardial infarction-CS; however, acute decompensated heart failure (ADHF)-CS accounts for most cases. We studied patients suffering ADHF-CS to identify clinical factors, early in their trajectory, associated with a higher probability of successful outcomes.METHODS:Consecutive patients with CS were evaluated (N=1162). We studied patients who developed ADHF-CS at our hospital (N=562). Primary end point was native heart survival (NHS), defined as survival to discharge without receiving advanced HF therapies. Secondary end points were adverse events, survival, major cardiac interventions, and hospital readmissions within 1 year following index hospitalization discharge. Association of clinical data with NHS was analyzed using logistic regression.RESULTS:Overall, 357 (63.5%) patients achieved NHS, 165 (29.2%) died, and 41 (7.3%) were discharged post advanced HF therapies. Of 398 discharged patients (70.8%), 303 (53.9%) were alive at 1 year. Patients with NHS less commonly suffered cardiac arrest, underwent intubation or pulmonary artery catheter placement, or received temporary mechanical circulatory support, had better hemodynamic and echocardiographic profiles, and had a lower vasoactive-inotropic score at shock onset. Bleeding, hemorrhagic stroke, hemolysis in patients with mechanical circulatory support, and acute kidney injury requiring renal replacement therapy were less common compared with patients who died or received advanced heart failure therapies. After multivariable adjustments, clinical variables associated with NHS likelihood included younger age, history of systemic hypertension, absence of cardiac arrest or acute kidney injury requiring renal replacement therapy, lower pulmonary capillary wedge pressure and vasoactive-inotropic score, and higher tricuspid annular plane systolic excursion at shock onset (allP<0.05).CONCLUSIONS:By studying contemporary patients with ADHF-CS, we identified clinical factors that can inform clinical management and provide future research targets. Right ventricular function, renal function, pulmonary artery catheter placement, and type and timing of temporary mechanical circulatory support warrant further investigation to improve outcomes of this devastating condition.

cardiac & cardiovascular systems
Modes of Death in Patients with Cardiogenic Shock in the Cardiac Intensive Care Unit: A Report from the Critical Care Cardiology Trials Network

David D. Berg,Sachit Singal,Michael Palazzolo,Vivian M. Baird-Zars,Fadel Bofarrag,Erin A. Bohula,Sunit-Preet Chaudhry,Mark W. Dodson,Dustin Hillerson,Patrick R. Lawler,Shuangbo Liu,Connor G. O'Brien,Barbara A. Pisani,Lekha Racharla,Robert O. Rowsell,Kevin S. Shah,Michael A. Solomon,Lakshmi Sridharan,Andrea D. Thompson,Sean van Diepen,Jason N. Katz,David A. Morrow,CCCTN Investigators

DOI: https://doi.org/10.1016/j.cardfail.2024.01.012

IF: 6.592

2024-02-23

Journal of Cardiac Failure

Abstract:Background There are limited data on how patients with cardiogenic shock (CS) die. Methods CCCTN is a research network of cardiac intensive care units coordinated by the TIMI Study Group (Boston, MA). Using standardized definitions, site investigators classified direct modes of in-hospital death for CS admissions (10/2021-09/2022). Mutually exclusive categories included 4 modes of cardiovascular death and 4 modes of non-cardiovascular death. Subgroups defined by CS type, preceding cardiac arrest (CA), use of temporary mechanical circulatory support (tMCS), and transition to comfort measures were evaluated. Results Among 1,068 CS cases, 337 (31.6%) died during the index hospitalization. Overall, mode of death was cardiovascular in 82.2%. Persistent CS was the dominant specific mode of death (66.5%), followed by arrhythmia (12.8%), anoxic brain injury (6.2%), and respiratory failure (4.5%). Patients with preceding CA were more likely to die from anoxic brain injury (17.1% vs. 0.9%;p<0.001) or arrhythmia (21.6% vs. 8.4%;p<0.001). Patients managed with tMCS were more likely to die from persistent shock (p<0.01), both cardiogenic (73.5% vs. 62.0%) and non-cardiogenic (6.1% vs. 2.9%). Conclusions Most deaths in CS are related to direct cardiovascular causes, particularly persistent CS. However, there is important heterogeneity across subgroups defined by preceding CA and use of tMCS.

cardiac & cardiovascular systems
Serial Shock Severity Assessment Within 72 Hours After Diagnosis: A Cardiogenic Shock Working Group Report

Van-Khue Ton,Song Li,Kevin John,Borui Li,Elric Zweck,Manreet K Kanwar,Shashank S Sinha,Jaime Hernandez-Montfort,A Reshad Garan,Rachel Goodman,Anthony Faugno,Maryjane Farr,Shelley Hall,Rachna Kataria,Maya Guglin,Esther Vorovich,Mohit Pahuja,Saraschandra Vallabhajosyula,Sandeep Nathan,Jacob Abraham,Neil M Harwani,Gavin W Hickey,Andrew D Schwartzman,Wissam Khalife,Claudius Mahr,Ju H Kim,Arvind Bhimaraj,Paavni Sangal,Qiuyue Kong,Karol D Walec,Peter Zazzali,Justin Fried,Daniel Burkhoff,Navin K Kapur

DOI: https://doi.org/10.1016/j.jacc.2024.04.069

2024-08-01

Abstract:Background: The Cardiogenic Shock Working Group-modified Society for Cardiovascular Angiography and Interventions (CSWG-SCAI) staging was developed to risk stratify cardiogenic shock (CS) severity. Data showing progressive changes in SCAI stages and outcomes are limited. Objectives: We investigated serial changes in CSWG-SCAI stages and outcomes of patients presenting with cardiogenic shock complicating acute myocardial infarction (MI-CS) and heart failure-related CS (HF-CS). Methods: The multicenter CSWG registry was queried. CSWG-SCAI stages were computed at CS diagnosis and 24, 48, and 72 hours. Results: A total of 3,268 patients (57% HF-CS; 27% MI-CS) were included. At CS diagnosis, CSWG-SCAI stage breakdown was 593 (18.1%) stage B, 528 (16.2%) stage C, 1,659 (50.8%) stage D, and 488 (14.9%) noncardiac arrest stage E. At 24 hours, >50% of stages B and C patients worsened, but 86% of stage D patients stayed at stage D. Among stage E patients, 54% improved to stage D and 36% stayed at stage E by 24 hours. Minimal SCAI stage changes occurred beyond 24 hours. SCAI stage trajectories were similar between MI-CS and HF-CS groups. Within 24 hours, unadjusted mortality rates of patients with any SCAI stage worsening or improving were 44.6% and 34.2%, respectively. Patients who presented in or progressed to stage E by 24 hours had the worst prognosis. Survivors had lower lactate than nonsurvivors. Conclusions: Most patients with CS changed SCAI stages within 24 hours from CS diagnosis. Stage B patients were at high risk of worsening shock severity by 24 hours, associated with excess mortality. Early CS recognition and serial assessment may improve risk stratification.
A Standardized and Regionalized Network of Care for Cardiogenic Shock

Behnam N Tehrani,Matthew W Sherwood,Carolyn Rosner,Alexander G Truesdell,Seiyon Ben Lee,Abdulla A Damluji,Mehul Desai,Shashank Desai,Kelly C Epps,Michael C Flanagan,Edward Howard,Nasrien Ibrahim,Jamie Kennedy,Hala Moukhachen,Mitchell Psotka,Anika Raja,Ibrahim Saeed,Palak Shah,Ramesh Singh,Shashank S Sinha,Daniel Tang,Timothy Welch,Karl Young,Christopher R deFilippi,Alan Speir,Christopher M O'Connor,Wayne B Batchelor

DOI: https://doi.org/10.1016/j.jchf.2022.04.004

Abstract:Background: The benefits of standardized care for cardiogenic shock (CS) across regional care networks are poorly understood. Objectives: The authors compared the management and outcomes of CS patients initially presenting to hub versus spoke hospitals within a regional care network. Methods: The authors stratified consecutive patients enrolled in their CS registry (January 2017 to December 2019) by presentation to a spoke versus the hub hospital. The primary endpoint was 30-day mortality. Secondary endpoints included bleeding, stroke, or major adverse cardiovascular and cerebrovascular events. Results: Of 520 CS patients, 286 (55%) initially presented to 34 spoke hospitals. No difference in mean age (62 years vs 61 years; P = 0.38), sex (25% vs 32% women; P = 0.10), and race (54% vs 52% white; P = 0.82) between spoke and hub patients was noted. Spoke patients more often presented with acute myocardial infarction (50% vs 32%; P < 0.01), received vasopressors (74% vs 66%; P = 0.04), and intra-aortic balloon pumps (88% vs 37%; P < 0.01). Hub patients were more often supported with percutaneous ventricular assist devices (44% vs 11%; P < 0.01) and veno-arterial extracorporeal membrane oxygenation (13% vs 0%; P < 0.01). Initial presentation to a spoke was not associated with increased risk-adjusted 30-day mortality (adjusted OR: 0.87 [95% CI: 0.49-1.55]; P = 0.64), bleeding (adjusted OR: 0.89 [95% CI: 0.49-1.62]; P = 0.70), stroke (adjusted OR: 0.74 [95% CI: 0.31-1.75]; P = 0.49), or major adverse cardiovascular and cerebrovascular events (adjusted OR 0.83 [95% CI: 0.50-1.35]; P = 0.44). Conclusions: Spoke and hub patients experienced similar short-term outcomes within a regionalized CS network. The optimal strategy to promote standardized care and improved outcomes across regional CS networks merits further investigation.
Clinical Presentation, Classification, and Outcomes of Cardiogenic Shock in Children

Kriti Puri,Jacob C. Jentzer,Joseph A. Spinner,Kyle D. Hope,Iki Adachi,Sebastian C. Tume,Hari P. Tunuguntla,Swati Choudhry,Antonio G. Cabrera,Jack F. Price

DOI: https://doi.org/10.1016/j.jacc.2023.11.019

IF: 24

2024-02-01

Journal of the American College of Cardiology

Abstract:Background Despite growing cardiogenic shock (CS) research in adults, the epidemiology, clinical features, and outcomes of children with CS are lacking. Objectives This study sought to describe the epidemiology, clinical presentation, hospital course, risk factors, and outcomes of CS among children hospitalized for acute decompensated heart failure (ADHF). Methods We examined consecutive ADHF hospitalizations (<21 years of age) from a large single-center retrospective cohort. Patients with CS at presentation were analyzed and risk factors for CS and for the primary outcome of in-hospital mortality were identified. A modified Society for Cardiovascular Angiography and Interventions shock classification was created and patients were staged accordingly. Results A total of 803 hospitalizations for ADHF were identified in 591 unique patients (median age 7.6 years). CS occurred in 207 (26%) hospitalizations. ADHF hospitalizations with CS were characterized by worse systolic function ( P = 0.040), higher B-type natriuretic peptide concentration ( P = 0.032), and more frequent early severe renal ( P = 0.023) and liver ( P < 0.001) injury than those without CS. Children presenting in CS received mechanical ventilation (87% vs 26%) and mechanical circulatory support (45% vs 16%) more frequently (both P < 0.001). Analyzing only the most recent ADHF hospitalization, children with CS were at increased risk of in-hospital mortality compared with children without CS (28% vs 11%; OR: 1.91; 95% CI: 1.05-3.45; P = 0.033). Each higher CS stage was associated with greater inpatient mortality (OR: 2.40-8.90; all P < 0.001). Conclusions CS occurs in 26% of pediatric hospitalizations for ADHF and is independently associated with hospital mortality. A modified Society for Cardiovascular Angiography and Interventions classification for CS severity showed robust association with increasing mortality.

cardiac & cardiovascular systems
Clinical Characteristics, Management and Outcomes in Cardiogenic Shock: insights from a high-volume Italian Cardiac Intensive Care Unit

Marco Giuseppe Del Buono,Giulia La Vecchia,Alessia D’Aiello,Daniela Pedicino,Gaetano Pinnacchio,Lorenzo Genuardi,Rocco Antonio Montone,Gianluigi Saponara,Antonio Di Renzo,Cristina Conte,Francesco Cribari,Francesco Moroni,Simone Filomia,Mattia Brecciaroli,Cristina AurigemmaMD,Giovanna Liuzzo,Carlo Trani,Francesco Burzotta,Tommaso Sanna

DOI: https://doi.org/10.1097/fjc.0000000000001584

IF: 3.271

2024-04-26

Journal of Cardiovascular Pharmacology

Abstract:Cardiogenic shock (CS) is a life-threatening condition. We aim to evaluate clinical characteristics, management and complication rate of patients with CS admitted in a high-volume hospital in Italy. We retrospectively reviewed the clinical, echocardiographic and laboratory data, therapeutic management and outcomes of patients with CS admitted to the Policlinico Gemelli (Rome) between January 1, 2020, and January 1, 2023. We included 96 patients (median age 71 years, IQR 60-79; 65 [68%] males), of whom 49 patients (51%) presented CS secondary to acute myocardial infarction and 60 (63%) with a de-novo presentation of CS. Dobutamine was the most frequently used inotrope and noradrenaline the most frequently used vasopressor (adopted in 56% and 82% of cases respectively). Forty-five (47%) patients died during the hospitalization. Non-survivors were older, presented a higher inflammatory burden at admission, elevated lactate levels, a greater increase in lactate levels, higher left ventricular filling pressures and worse right ventricular function. C-Reactive Protein (CRP) levels [odd ratio (OR) 1.03, 95% confidence interval (CI) [1.00;1.04], p=0.027), lactate levels at admission (OR 3.49, 95% CI [1.59;7.63], p=0.02) and increase in lactate levels (OR 2.8, 95% CI [1.37;5.75], p=0.005) were independent predictors of in-hospital all cause death. Our data contribute to assess the regional variations in management and outcomes of patients with CS. We observed a high mortality and complication rate. Lactate acidosis and CRP measured at admission, may help in identifying patients at higher risk of adverse in-hospital outcomes.

pharmacology & pharmacy,cardiac & cardiovascular systems
Cardiogenic shock in general intensive care unit: a Nationwide prospective analysis of epidemiology and outcome

Guido Tavazzi,Giovanni Tricella,Elena Garbero,Anna Zamperoni,Michele Zanetti,Stefano Finazzi

DOI: https://doi.org/10.1093/ehjacc/zuae108

2024-09-20

Abstract:Abstract Background Cardiogenic shock (CS) is a life-threatening disease burdened by a mortality up to 50%. The epidemiology has changed with non-ischemic aetiologies being predominant although data was mainly derived from patients admitted to dedicated acute cardiac care. We report the epidemiology and outcome of patients with CS admitted to general intensive care unit (ICU). Methods Prospective multicentric epidemiological study including 314 general ICU adhering to the GiViTI Nationwide registry from 2011 to 2018, excluding cardiac arrest. The primary endpoint of the study was mortality. The association between clinical factors and mortality was evaluated using a logistic regression model. The Odds Ratios of the covariates quantify their association with mortality during hospitalization. Results 11052 patients admitted to general ICU (incidence 2.17%; median age 72 (IQR [66-81]), 38.7% were women) with CS were included. Fourthy-seven percent of patients had more than 3 organ insufficiency at the time of admission. The most common CS aetiologies were: left heart failure LHF- 5247–47.5%), acute myocardial infarction (AMI - 3612–32.6%); right heart failure (RHF- 515–4.6%) and biventricular failure (532- 4.8%). 85.5% were mechanically ventilated during the ICU hospitalization. The overall ICU mortality was 44.8%, increasing to 53.4% during the hospitalization in the index hospital and to 54.3% at the latest hospital. RHF-CS patients exhibited the highest mortality risk (OR: 1.19 95% CI [0.94 − 1.50]; p < 0.001), followed by biventricular-CS OR 1.04 95% CI [0.82–1.32]. Respiratory failure (OR 1.13 [95%CI 1.08–1.19]), coagulation disorder (1.17 (95% CI 1.1–1.24), renal dysfunction (OR 1.55 [95% CI 1.50-1.61] and neurological alteration (OR 1.45 [95% CI 1.39–1.50]) were associated with worsen outcome along with severe hypotension (systolic blood pressure < 70 mmHg- OR 2.35 95% CI [2.06–2.67]), increasing age (OR 2.21 95% CI [2.01–2.42] and longer ICU stay prior to admission (2-fold increase for each 4.7 days). Conclusions In the general ICU the aetiology of CS, excluding cardiac arrest, remains characterized mostly by LHF with RHF-CS burdened by higher mortality. Multiorgan failure at admission and longer hospital stay before ICU admission predispose to worsen outcome.

cardiac & cardiovascular systems
Current Spectrum and Outcomes of Infarct-Related Cardiogenic Shock: Insights from the CULPRIT-SHOCK Registry and RCT

Uwe Zeymer,Tobias Heer,Taoufik Ouarrak,Ibrahim Akin,Marko Noc,Janina Stepinska,Keith Oldroyd,Pranas Serpytis,Giles Montalescot,Kurt Huber,Stephan Windecker,Stefano Savonitto,Christiaan Vrints,Steffen Schneider,Steffen Desch,Holger Thiele

DOI: https://doi.org/10.1093/ehjacc/zuae020

2024-02-13

Abstract:Abstract Background We analysed consecutive patients with acute myocardial infarction complicated by cardiogenic shock (CS) who were enrolled into the CULPRIT-SHOCK randomized controlled trial (RCT) and those with exclusion criteria who were included into the accompanying registry. Methods In total, 1,075 patients with infarct-related CS were screened for CULPRIT-SHOCK in 83 specialised centres in Europe; 369 of them had exclusion criteria for the RCT and were enrolled into the registry. Patients were followed over 1-year. Results Mean age was 68 years and 260 (25 %) were women. 13.5 %, 30.9 %, and 55.6 % had 1-vessel, 2-vessel, and 3-vessel coronary artery disease (CAD), respectively. Significant left main (LM) coronary artery stenosis was present in 8.0 %. 54.2 % of the patients had cardiac arrest before admission. TIMI 3 patency of the infarct vessel after PCI was achieved in 83.6 % of all patients. Mechanical circulatory support was applied in one third of patients. Total mortality after 30 days and one year was 47.6 % and 52.9 %. Mortality after one year was highest in patients with LM coronary artery stenosis (63.5 %), followed by 3-vessel- (56.6 %), 2-vessel- (49.8 %), and 1-vessel-CAD (38.6 %), respectively. Mechanical complications were rare (21/1008; 2.1 %) but associated with a high mortality of 66.7 % after 1 year. Conclusions In specialised centres in Europe short- and long-term mortality of patients with infarct-related CS treated with an invasive strategy is still high and mainly depending on the extent of coronary artery disease. Therefore, there is still need for improvement of care to improve prognosis of infarct-related CS.

cardiac & cardiovascular systems
Cold and heat injury.

S. Kumari,A. Dutta

1988-10-01

Indian Pediatrics

Abstract:
Pathophysiologic Vasodilation in Cardiogenic Shock and Its Impact on Mortality

Miguel A. Chavez,McHale Anderson,Christos P. Kyriakopoulos,Monte Scott,Elizabeth Dranow,Eleni Maneta,Rana Hamouche,Iosif Taleb,Jacy Leon,Benjamin Kogelschatz,Jake Goldstein,Filio Billia,David A. Baran,Behnam Tehrani,Matt Goodwin,Craig H. Selzman,Joseph E. Tonna,James C. Fang,Stavros G. Drakos,Thomas C. Hanff

DOI: https://doi.org/10.1161/circheartfailure.124.011827

2024-07-26

Circulation Heart Failure

Abstract:Circulation: Heart Failure, Ahead of Print. BACKGROUND:Cardiogenic shock (CS) mortality remains near 40%. In addition to inadequate cardiac output, patients with severe CS may exhibit vasodilation. We aimed to examine the prevalence and consequences of vasodilation in CS.METHODS:We analyzed all patients hospitalized at a CS referral center who were diagnosed with CS stages B to E and did not have concurrent sepsis or recent cardiac surgery. Vasodilation was defined by lower systemic vascular resistance (SVR), higher norepinephrine equivalent dose, or a blunted SVR response to pressors. Threshold SVR values were determined by their relation to 14-day mortality in spline models. The primary outcome was death within 14 days of CS onset in multivariable-adjusted Cox models.RESULTS:This study included 713 patients with a mean age of 60 years and 27% females; 14-day mortality was 28%, and 38% were vasodilated. The median SVR was 1308 dynes•s•cm−5(interquartile range, 870–1652), median norepinephrine equivalent was 0.11 μg/kg per minute (interquartile range, 0–0.2), and 28% had a blunted pressor response. Each 100-dynes•s•cm−5decrease in SVR below 800 was associated with 20% higher mortality (adjusted hazard ratio, 1.23;P=0.004). Each 0.1-μg/kg per minute increase in norepinephrine equivalent dose was associated with 15% higher mortality (adjusted hazard ratio, 1.12;P<0.001). A blunted pressor response was associated with a nearly 2-fold mortality increase (adjusted hazard ratio, 1.74;P=0.003).CONCLUSIONS:Pathophysiologic vasodilation is prevalent in CS and independently associated with an increased risk of death. CS vasodilation can be identified by SVR <800 dynes•s•cm−5, high doses of pressors, or a blunted SVR response to pressors. Additional studies exploring mechanisms and treatments for CS vasodilation are needed.

cardiac & cardiovascular systems

[Long-term follow-up of reconstruction of the pulmonary artery using homograft].

Epidemiology of cardiogenic shock using the Shock Academic Research Consortium (SHARC) consensus definitions

Phenotyping Cardiogenic Shock

Association of Hemometabolic Trajectory and Mortality: Insights From the Cardiogenic Shock Working Group Registry

Evaluation of repeated machine learning-based phenotyping in patients with cardiogenic shock

Contemporary approach to cardiogenic shock care: a state-of-the-art review

Prognostic Performance of the IABP-SHOCK II Risk Score Among Cardiogenic Shock Subtypes in the Critical Care Cardiology Trials Network Registry

Sex Differences in Characteristics, Resource Utilization, and Outcomes of Cardiogenic Shock: Data From the Critical Care Cardiology Trials Network (CCCTN) Registry

Mixed Cardiogenic Shock: A Proposal for Standardized Classification, a Hemodynamic Definition, and Framework for Management

American Heart Association Cardiogenic Shock Registry: Design and Implementation

A Standardized and Comprehensive Approach to the Management of Cardiogenic Shock

Clinical Characteristics and Outcomes of Patients Suffering Acute Decompensated Heart Failure Complicated by Cardiogenic Shock

Modes of Death in Patients with Cardiogenic Shock in the Cardiac Intensive Care Unit: A Report from the Critical Care Cardiology Trials Network

Serial Shock Severity Assessment Within 72 Hours After Diagnosis: A Cardiogenic Shock Working Group Report

A Standardized and Regionalized Network of Care for Cardiogenic Shock

Clinical Presentation, Classification, and Outcomes of Cardiogenic Shock in Children

Clinical Characteristics, Management and Outcomes in Cardiogenic Shock: insights from a high-volume Italian Cardiac Intensive Care Unit

Cardiogenic shock in general intensive care unit: a Nationwide prospective analysis of epidemiology and outcome

Current Spectrum and Outcomes of Infarct-Related Cardiogenic Shock: Insights from the CULPRIT-SHOCK Registry and RCT

Cold and heat injury.

Pathophysiologic Vasodilation in Cardiogenic Shock and Its Impact on Mortality